Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HCA Health Inc (HCA) vs JBS N.V. Class A Common Shares (JBS) Price & Performance

HCA Health IncTrade
JBS N.V. Class A Common SharesTrade

Price performance (Past 24H)

Key statistics

HCA Health Inc vs JBS N.V. Class A Common Shares — how do they compare? HCA Health Inc trades at $470.49 (market cap $99.75B), while JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B). The key difference: HCA Health Inc is far larger — about 7.2× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.38%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and JBS N.V. Class A Common Shares for 0 Days on average.

HCAJBS
Market Cap
$99.75B$13.86B
Volume
1,083,2314,980,049
Sector
HealthConsumer Staples
52-Week High
$545.13$18.42
52-Week Low
$361.32$10.86
Typical Hold Time
76 Days0 Days
Enterprise Value
$150.29B$34.83B
Dividend Yield
0.68%10.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HCA Health Inc

HCA Healthcare's stock trades at $470.44, up 2.58% today, with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $75.60B in 2025, with a net income margin of 8.77%, while the P/E ratio of 15.45 suggests reasonable valuation. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations, creating mixed sentiment.

The outlook is positive due to consistent earnings performance and analyst buy ratings, but risks include high debt levels and regulatory scrutiny. Investment opportunity lies in operational efficiency and demand growth, though investors should monitor legal developments and debt management.

JBS N.V. Class A Common Shares

JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.

The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HCA
49% Buy51% Sell
Avg holding period · 76 Days
JBS
100% Buy0% Sell
Avg holding period · 0 Days

About HCA Health Inc

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.

Read more on HCA →

About JBS N.V. Class A Common Shares

JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.

Read more on JBS →